The aim of this investigation was to develop receiver and extraction fluids, and subsequently validate an analytical method to quantify the permeation and penetration of flurbiprofen into human pharynx tissue using a Franz diffusion cell. The solubility and stability of flurbiprofen in a suitable receiver fluid, and a suitable extraction method and fluid to recover and quantitate flurbiprofen from human pharynx tissue, were investigated using high-performance liquid chromatography (HPLC). The potential interference of human pharynx tissue in the receiver fluid was also investigated. 
.
To determine the penetration and permeation of drugs through tissues, the Franz diffusion cell method is often used to mimic in vivo conditions (Azzi et al., 2006; Franz, 1975; Ingram, Bartlett, Brown, Marriott, & Whitfield, 2003; Ng, Rouse, Sanderson, Meidan, & Eccleston, 2010) and has been used to determine the permeation rate of flurbiprofen through human skin (Takeuchi et al., 2011) . Highperformance liquid chromatography (HPLC) has been used previously to assess the penetration of drugs into tissues (Azzi et al., 2006; Dhiman, Dhiman, & Sawant, 2009; Casey et al., 2017; Frosini, Bond, Loeffler, & Larner, 2017; Souza & Maia Campos, 2017) , including the quantitation of flurbiprofen (Locatelli, Ferrone, Cifelli, Barbacane, & Carlucci, 2014; Yilmaz & Erdem, 2015) .
The aim of this investigation was to develop receiver and extraction fluids, and subsequently validate an analytical method to quantify the permeation and penetration of flurbiprofen into human pharynx tissue using a Franz diffusion cell (Soham Scientific, Ely, UK). 
| EXPERIMENTAL

| HPLC for the quantitation of flurbiprofen
The HPLC methodology was developed using the LC2030C HPLC system (Shimadzu UK Ltd, Milton Keynes, UK) and Empower 3 Data Processing Software (Waters UK, Elstree, UK). Initial implementation of the HPLC method was conducted with flurbiprofen in a generic sample diluent (methanol-water) to ensure that the method was suitable for preliminary sample analysis before validation, and to provide information that the method was likely to be suitable for validation. The initial calibration standards were analyzed three times and QC standards were analyzed six times.
Following the receiver and extraction fluid development, the HPLC method was validated using both solutions as sample diluent based on the acceptance criteria of the European Medicines Agency 
| Test drug
A flurbiprofen laboratory working standard (Reckitt Benckiser, manufactured in Bangplee, Thailand) was used for this investigation.
| Calibration/QC standards
Standards for initial implementation were 0.1-100 μg/mL (60:40 v/v methanol-water). Following selection of suitable receiver and extraction fluids, the final calibration and quality control (QC) standards for validation were prepared from separate flurbiprofen stock solutions (500 μg/mL). The calibration standards ranged from 0.045 to 100.0 μg/mL (100, 85, 60, 40, 6, 0.15, 0 .045 μg/mL) in receiver fluid and extraction fluid and the QC standards ranged from 0.045 to 85.0 μg/mL (85, 60, 40, 0.15, 0 .045 μg/mL) in receiver and extraction fluids.
| Human pharynx tissue
Human pharynx tissue ethically sourced from cadavers was supplied by Ethical Tissue (University of Bradford, UK; Research Ethics Committee reference 220367) and was stored at −20°C prior to use. The tissue was cut to~0.5-1 cm 2 prior to use in the development of receiver and extraction fluids and extraction methods.
| Development of receiver fluid for the Franz diffusion cell
A suitable receiver fluid was required to ensure the permeation of the stirred. An aliquot of the diluted sample was analyzed using the HPLC method. The stability of flurbiprofen in the potential receiver fluids was assessed at 2-8 and 37°C at 24 and 48 h, and 5 days, using the HPLC method.
The potential interference of human pharynx tissue in the receiver fluid with the flurbiprofen peak in the HPLC method was also investigated, to ensure that no issues would be encountered in the full experiment. Pharynx tissue cut into~0.6 cm 2 sections was added to 28 mL of receiver fluid and stored in a 37°C water bath for 24 h. From the receiver fluid, 20 mL was removed and added to 5 mg of flurbiprofen and mixed by inversion. The solution was then made up to 100 mL using receiver fluid and analyzed by HPLC. Low concentration 1 μg/mL = 0.86% Relative SD < 2% Meets specification at three concentrations Medium concentration 10 μg/mL = 0.28% High concentration 80 μg/mL = 0.08% System suitability (1 μg/mL) Capacity factor K = 9.61 K > 2 Meets specification Tailing by inversion. The solution was then made up to 100 mL using receiver fluid and analyzed by HPLC to confirm that there were no interfering peaks from the tissue. Details of a small-scale experimental procedure are outlined in section S1.
| RESULTS
| HPLC
During assessment of the analytical method, the absorption spectra of the flurbiprofen peak and the lambda max were determined to be 247 nm. This detection wavelength was then set to ensure that the greatest level of sensitivity could be achieved.
Following implementation (Table 1) Table 2 ). The final HPLC system conditions are described in Table 3 .
| Receiver fluid
All receiver fluids demonstrated sufficient solubility (at least 10-fold greater than the maximum amount of flurbiprofen anticipated to permeate the pharynx tissue), with saturated solubility of the drug ranging from 0.12% w/w (PBS) to 0.14% w/w (0.2% w/v Brij 98 in PBS).
Acceptable stability (95-105% compared with t = 0) of flurbiprofen from all three receiver fluids was observed across the 5 day stability period at both 2-8 and 37°C (Table 4) (Akhlaq et al., 2011; Hussain, Al-Ajmi, Amir, & Ali, 2016; Yilmaz & Erdem, 2015) . 
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